Cargando…

Erythropoietin and Fibroblast Growth Factor 23 in Autosomal Dominant Polycystic Kidney Disease Patients

Detalles Bibliográficos
Autores principales:	Hanudel, Mark R., Salusky, Isidro B., Pereira, Renata C., Wang, Wei, You, Zhiying, Nowak, Kristen L., Brosnahan, Godela M., Torres, Vicente E., Chapman, Arlene B., Perrone, Ronald D., Steinman, Theodore I., Bae, Kyongtae T., Gitomer, Berenice Y., Chonchol, Michel B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2019
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6895647/ https://www.ncbi.nlm.nih.gov/pubmed/31844811 http://dx.doi.org/10.1016/j.ekir.2019.08.010

Ejemplares similares

Pain and Obesity in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis of the Halt Progression of Polycystic Kidney Disease (HALT-PKD) Studies
por: Nowak, Kristen L., et al.
Publicado: (2021)

Affected parent sex and severity of autosomal dominant polycystic kidney disease: a retrospective cohort study
por: Nowak, Kristen L., et al.
Publicado: (2018)

Determinants of Progression in Early Autosomal Dominant Polycystic Kidney Disease: Is it Blood Pressure or Renin-Angiotensin-Aldosterone-System Blockade?
por: Brosnahan, Godela M., et al.
Publicado: (2018)

PKD1 Compared With PKD2 Genotype and Cardiac Hospitalizations in the Halt Progression of Polycystic Kidney Disease Studies
por: Steele, Cortney, et al.
Publicado: (2021)

Quest for the Cure: Testing the Old and New to Prevent Progression of Autosomal Dominant Polycystic Kidney Disease
por: Brosnahan, Godela
Publicado: (2019)

Longitudinal Assessment of Left Ventricular Mass in Autosomal Dominant Polycystic Kidney Disease
por: Dad, Taimur, et al.
Publicado: (2018)

A Drug Development Tool for Trial Enrichment in Patients With Autosomal Dominant Polycystic Kidney Disease
por: Perrone, Ronald D., et al.
Publicado: (2017)

Metabolic profiling in children and young adults with autosomal dominant polycystic kidney disease
por: Baliga, Madhurima M., et al.
Publicado: (2021)

Curcumin therapy to treat vascular dysfunction in children and young adults with autosomal dominant polycystic kidney disease: Design and baseline characteristics of participants
por: Nowak, Kristen L., et al.
Publicado: (2020)

Developments in the management of autosomal dominant polycystic kidney disease
por: Masoumi, Amirali, et al.
Publicado: (2008)

Weight loss and cystic disease progression in autosomal dominant polycystic kidney disease
por: Hopp, Katharina, et al.
Publicado: (2021)

CD8(+) T cells modulate autosomal dominant polycystic kidney disease progression
por: Kleczko, Emily K., et al.
Publicado: (2018)

Total Kidney Volume Is a Prognostic Biomarker of Renal Function Decline and Progression to End-Stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney Disease
por: Perrone, Ronald D., et al.
Publicado: (2017)

Prognostic Enrichment Design in Clinical Trials for Autosomal Dominant Polycystic Kidney Disease
por: Steinman, Theodore
Publicado: (2016)

Prognostic Value of Fibroblast Growth Factor 23 in Autosomal Dominant Polycystic Kidney Disease
por: El Ters, Mireille, et al.
Publicado: (2021)

Urinary Proteomic Biomarkers for Diagnosis and Risk Stratification of Autosomal Dominant Polycystic Kidney Disease: A Multicentric Study
por: Kistler, Andreas D., et al.
Publicado: (2013)

Correction: Urinary Proteomic Biomarkers for Diagnosis and Risk Stratification of Autosomal Dominant Polycystic Kidney Disease: A Multicentric Study
por: Kistler, Andreas D., et al.
Publicado: (2013)

Tolvaptan suppresses monocyte chemotactic protein-1 excretion in autosomal-dominant polycystic kidney disease
por: Grantham, Jared J., et al.
Publicado: (2017)

Characterization of Primary Cilia in Osteoblasts Isolated From Patients With ADPKD and CKD
por: Pereira, Renata C, et al.
Publicado: (2021)

Relationship between caffeine intake and autosomal dominant polycystic kidney disease progression: a retrospective analysis using the CRISP cohort
por: McKenzie, Katelyn A., et al.
Publicado: (2018)

A comparison of ultrasound and magnetic resonance imaging shows kidney length predicts chronic kidney disease in autosomal dominant polycystic kidney disease
por: Bhutani, Harpreet, et al.
Publicado: (2015)

Autosomal dominant polycystic kidney
por: Gudadhe, Rugaved Raghavendra, et al.
Publicado: (2022)

Medical resource utilization and costs associated with autosomal dominant polycystic kidney disease in the USA: a retrospective matched cohort analysis of private insurer data
por: Knight, Tyler, et al.
Publicado: (2015)

Prognostic Enrichment Design in Clinical Trials for Autosomal Dominant Polycystic Kidney Disease: The TEMPO 3:4 Clinical Trial
por: Irazabal, Maria V., et al.
Publicado: (2016)

Tolvaptan and Kidney Pain in Patients With Autosomal Dominant Polycystic Kidney Disease: Secondary Analysis From a Randomized Controlled Trial
por: Casteleijn, Niek F., et al.
Publicado: (2016)

Tolerability of Aquaretic-Related Symptoms Following Tolvaptan for Autosomal Dominant Polycystic Kidney Disease: Results From TEMPO 3:4
por: Devuyst, Olivier, et al.
Publicado: (2017)

Pharmacokinetics and Pharmacodynamics of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Phase 2 Trials for Dose Selection in the Pivotal Phase 3 Trial
por: Shoaf, Susan E., et al.
Publicado: (2017)

Obesity, Weight Loss, Lifestyle Interventions, and Autosomal Dominant Polycystic Kidney Disease
por: Steele, Cortney, et al.
Publicado: (2022)

Autosomal dominant polycystic kidney disease in Colombia
por: Camargo, Jessica T., et al.
Publicado: (2023)

Patient-reported outcome measures for pain in autosomal dominant polycystic kidney disease: A systematic review
por: Natale, Patrizia, et al.
Publicado: (2021)

Prevalence of autosomal dominant polycystic kidney disease in the European Union
por: Willey, Cynthia J., et al.
Publicado: (2017)

Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial
por: Torres, Vicente E, et al.
Publicado: (2018)

There is no association between autosomal dominant polycystic kidney disease and left ventricular non-compaction cardiomyopathy: a cardiac magnetic resonance imaging study
por: Akhtari, Shadi, et al.
Publicado: (2016)

Hypertension in autosomal-dominant polycystic kidney disease (ADPKD)
por: Sans-Atxer, Laia, et al.
Publicado: (2013)

Nephrotic syndrome and autosomal dominant polycystic kidney disease
por: Visciano, Bianca, et al.
Publicado: (2012)

Umbilical hernia in autosomal dominant polycystic kidney disease
por: Hattori, Yoshinari, et al.
Publicado: (2014)

Diagnostic Imaging of Autosomal Dominant Polycystic Kidney Disease
por: Gradzik, Monika, et al.
Publicado: (2016)

Obturator hernia in autosomal dominant polycystic kidney disease
por: Jung, Jong Hwan, et al.
Publicado: (2018)

Autosomal dominant polycystic kidney disease: updated perspectives
por: Rastogi, Anjay, et al.
Publicado: (2019)

Educational Case: Autosomal Dominant Polycystic Kidney Disease
por: Frazier, Ryan L., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_n5f4a1kolhpihh24mal3jhnsdu